Enable job alerts via email!
Boost your interview chances
Create a job specific, tailored resume for higher success rate.
An established industry player is seeking a Contractor for DMPK and Bioanalysis, offering a unique opportunity to lead the development of large molecule drug candidates. This role involves overseeing nonclinical studies, collaborating with a skilled team, and contributing to regulatory submissions. Candidates with strong backgrounds in pharmacokinetics and drug metabolism will find this position rewarding. Join a forward-thinking company committed to advancing cancer therapies and making a significant impact in the field. If you are passionate about improving patient outcomes and ready to take on a leadership role in DMPK, this is the perfect opportunity for you.
Join to apply for the Contractor, DMPK and Bioanalysis role at Syndax Pharmaceuticals
1 week ago Be among the first 25 applicants
Join to apply for the Contractor, DMPK and Bioanalysis role at Syndax Pharmaceuticals
Syndax Pharmaceuticals is looking for a Contractor, DMPK and Bioanalysis
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
Syndax is seeking a motivated individual with accountability for overseeing all aspects of DMPK relating to the development of large molecule drug candidates, including the design, conduct, and reporting of nonclinical DMPK studies as well as bioanalysis of nonclinical and clinical studies data. Reporting directly to the senior director, head of clinical pharmacology, you will have the opportunity to collaborate with a highly skilled team and make a significant impact on our scientific endeavors. This is an exciting opportunity to be the DMPK and bioanalytical lead for a potential NDA.
While our corporate headquarters are located in New York City, this position is open to candidates from any location with a preference for east coast locations.
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj (revumenib), an FDA-approved menin inhibitor, and Niktimvo (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Pharmaceuticals is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.